Abstract: Psoriasis is an immune-mediated, chronic, inflammatory and systemic disease induced by polygenic and multiple environmental factors. Due to the unavailability of a cure, psoriasis significantly affects patients' quality of life. Although biological therapies have greatly improved the treatment of psoriasis and therapeutic antibodies have become the mainstay of psoriasis treatment, extensive unmet medical need still remains and the roles of small-molecule drugs for psoriasis treatment are irreplaceable. Comprehensive analysis of clinical advances and patent situations of small-molecule drugs for psoriasis were reviewed in this paper.